Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
212
datasets available to search
ShareScore release 0.9.0
Dataset results
212 results for “ivermectin”
Data from: Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian Aboriginal community
Open the record for dataset details and reuse information.
Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p<0.002 for effect by state, then 13-fold increase after ivermectin use restricted
Open the record for dataset details and reuse information.
Data from: Potential interaction between clorsulon and ivermectin for malaria vector control
Open the record for dataset details and reuse information.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
<p><b>Objective:</b> Ivermectin has been suggested as a treatment for COVID-19.This randomised control trial was conducted to test the efficacy of Ivermectin in the treatment of mild and moderate COVID-19.</p> <p><b>Design:</b> Parallel, double blind, randomised, placebo controlled trial</p> <p><b>Setting:</b> A tertiary care dedicated COVID-19 hospital in Bihar, India</p> <p><b>Participants:</b> Adult patients (> 18 years) admitted with mild to moderate COVID 19 disease (saturation > 90% on room air, respiratory rate < 30 and no features of shock) with no contraindications to ivermectin and willing to participate in the study</p> <p><b>Intervention:</b> Patients in the intervention arm were given ivermectin 12 mg on day 1 and day 2 of admission. Patients in the placebo arm were given identical looking placebo tablets. Rest of the treatment was continued as per the existing protocol and the clinical judgment of the treating teams.</p> <p><b>Outcome Measures:</b> The primary outcome measure was a negative RT-PCR test for SARS-CoV-2 on day 6 of admission. The secondary outcome measures were symptom status on day 6, discharge status on day 10, admission to ICU, need for invasive mechanical ventilation and in-hospital mortality.</p> <p><b>Results:</b> A total of 115 patients were enrolled for the study of which 112 were included in the final analysis. Of them, 55 were randomised to the intervention arm while 57 were randomised to the placebo arm. There was no significant difference in the baseline characteristics of the two arms. There was no significant difference in the primary outcome, i.e. negative RT-PCR status on day 6 between the two groups. Similarly, there was no significant difference between the two groups in most of the secondary outcome measures, viz. symptom status on day 6, discharge status on day 10, admission to ICU, and need for invasive mechanical ventilation. However, while there was no in-hospital mortality in the intervention arm, there were 4 deaths in the placebo arm. As a result, all patients in the intervention arm (n=56) were successfully discharged as compared to 93.1% (n=54/58) in the placebo arm (RR 1.1, 95% CI 1.0 to 1.2, p=0.019).</p> <p><b>Conclusion:</b> There was no difference in the primary outcome i.e. negative RT-PCR status on day 6 of admission with the use of ivermectin. However, a significantly higher proportion of patients were discharged alive from the hospital when they received ivermectin.</p>
Figure 7 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 7 Histopathological section of mice skin (clobetasol control group) showing hyperkeratosis (black arrow), absence of parakeratosis & Munro's abscess. And epidermal granular layer (yellow arrow) with mild acanthosis, mild papillary thinning, and few rete ridges (green arrow). The dermis shows mild lymphocytic infiltrate. H&E stain (4×,10×).
Figure 11 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 11 Comparison between induced non-treated group and all induced treated groups regarding histopathological scores (Baker score) and observational score (PASI score).
Figure 4 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 4 Histopathological section of mice skin (healthy control group) showing normal skin architecture including K = keratin, E = epidermis, D = dermis, AD = adnexa, S.C = subcutaneous tissue, M = muscles, B.V = blood vessels. H&E stain (4×,10×).
Figure 3 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 3 Scoring for skin inflammation severity, the pictures show different inflammation levels of the dorsal skin on which the test substances were applied on day 8 of the Experiment. A. Represents the healthy group; B. Represents the IMQ-induced group; C. Represents the vehicle group; D. Represents Clobetasol treated group; E. Represents the Ivermectin treated group; F. Represents Ivermectin + Clobetasol treated group.
Figure 6 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 6 Histopathological section of mice skin (vehicle group) showing hyperkeratosis, parakeratosis (black arrow), with focal neutrophilic infiltration (the Munro's abscess) in red arrow, with epidermal acanthosis and thinning papillae and elongated rete ridges (green arrow), and lack of granular layer. The dermis shows moderate to severe inflammatory lymphocytic infiltration (blue arrow). H&E stain (4×,10×).
Figure 9 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 9 Histopathological section of mice skin (Ivermectin treatment group) showing mild keratosis (black arrow), with the absence of Munro's abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning (green arrow). The dermis shows severe lymphocytic infiltrate. H&E stain (4×,10×).
Figure 2 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 2 Induction of Psoriasis in mice. A Mouse before Induction. B Mouse after Induction by Imiquimod cream.
Figure 8 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 8 Histopathological section of mice skin (Ivermectin treatment group) showing mild keratosis (black arrow), with the absence of Munro's abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning (green arrow). The dermis shows severe lymphocytic infiltrate. H&E stain (4×,10×, 40×).
Figure 10 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 10 Comparison between induced non-treated group and all induced treated groups regarding tissue biomarkers (IL-10, IL-17, TNF-a, and VEGF).
Figure 5 from: Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
Figure 5 Histopathological section of mice skin (induction group) showing hyperkeratosis, parakeratosis (black arrow), with multifocal dense neutrophilic infiltration (the Munro's abscess) in red arrow, with epidermal acanthosis and thinning papillae and rete ridges appearance (green arrow), and lack of granular layer. The dermis shows moderate to severe inflammatory lymphocytic infiltration (blue arrow). H&E stain (4×,10×, 40×).
Fig. 2 in Considering ivermectin for treatment of schistosomiasis
Fig. 2 Liver histology of schistosome-infected mice treated with ivermectin or artemisone on days 41 and 42 postinfection
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
ClinicalTrials.gov study NCT02806414. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
ClinicalTrials.gov study NCT05305560. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ivermectin and Nitazoxanide Combination Therapy for COVID-19
ClinicalTrials.gov study NCT04360356. IPD Sharing: NO. Countries: 0. Publications: 16.
Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19
ClinicalTrials.gov study NCT04551755. IPD Sharing: NO. Countries: 0. Publications: 12.
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
ClinicalTrials.gov study NCT04343092. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.